The Drug Enforcement Administration (DEA) has just ended what has been described as a 52-year monopoly on the cultivation of cannabis for research purposes.
Several large-scale cannabis growers have been awarded contracts to produce marijuana for federal research, a move that will hopefully go a long way toward demonstrating what many state and foreign governments already know: cannabis has powerful medicinal properties, particularly for pain control.
Award-winning journalist Bruce Williams described marijuana produced on the 12-acre farm at the National Center for Natural Products Development at the University of Mississippi, the only federally approved cannabis supplier for research purposes in the United States, as “terrible, with low THC content “. “
That “fool” has caused several public relations disasters. In a case, Johns Hopkins University withdrew from a medical cannabis trial because they requested marijuana with at least 12% THC and were unable to obtain it from the federal agency. The Scottsdale Research Institute (SRI) scientists who participated in the trial, talking to PBS at the time, said what they received was contaminated with mold and “didn’t look like grass [or] smells like grass. “
Another case saw a Massachusetts-based scientist file a lawsuit against the DEA for not reviewing your application to grow marijuana for a lawsuit for MAPS (Multidisciplinary Association for Psychedelic Studies). It emerged that the DEA had received 33 such requests since 2016 that it appeared to have simply archived.
However, on May 14, the DEA announced quietly that it would “soon register additional entities authorized to produce marijuana for research purposes,” and that those entities would include the SRI, who received the moldy schwag and actually performed a important role in this policy change.
One lawsuit, Scottsdale Research v. DOJ / DEA, came out a note from 2018 that suggested that the DEA’s Mississippi monopoly was a violation of federal law, as well as certain US treaty obligations.
The memo, published by the Office of Legal Counsel, it was kept secret, even in the face of repeated attempts by the legislator to reveal it and find out why, since 2016, the 33 plaintiffs had been repeatedly ignored.
Finally, SRI’s lawsuit obtained the US Court of Appeals to order the DEA to answer why it had not processed the SRIs or the other 32 requests.
Now the DEA has capitulated, recently publicly approve multiple apps.
Matthew Zorn, an attorney who co-led the FOIA-based lawsuit, said Leafly that scientists will now be able to conduct research on the type of cannabis that people are using.
“Many people may not appreciate the importance of that, with [national cannabis] legalization around the corner, ”he told Bruce Williams. “We don’t know when, but the need for this research is urgent. We can start growing as quickly as possible and have a supply for researchers to get good data. “
SPREAD the good news: Share this story with friends …